Michael Ulz
Stock Analyst at Morgan Stanley
(4.56)
# 272
Out of 5,043 analysts
99
Total ratings
56.67%
Success rate
29.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $34.42 | +196.34% | 4 | Oct 23, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $75 → $81 | $70.02 | +15.68% | 4 | Oct 16, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $86 → $90 | $70.86 | +27.01% | 7 | Oct 16, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $6.34 | +231.23% | 8 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $405 → $475 | $463.43 | +2.50% | 12 | Oct 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $7.30 | +242.47% | 12 | May 9, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $7.44 | +168.82% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.47 | +790.69% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $10.70 | +171.03% | 1 | Mar 10, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $2.25 | +788.89% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.38 | +624.64% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $53.77 | +78.54% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $17.12 | +203.74% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $38.00 | -28.95% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.65 | +324.24% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $13.10 | +106.11% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $2.08 | +861.54% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.85 | +1,068.83% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.79 | +1,165.82% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.75 | -36.84% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.98 | +401.67% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $9.78 | +5,012.47% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $33.53 | +138.59% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $8.67 | +73.01% | 3 | Jul 12, 2017 |
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $34.42
Upside: +196.34%
Mirum Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $75 → $81
Current: $70.02
Upside: +15.68%
Ionis Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $86 → $90
Current: $70.86
Upside: +27.01%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $6.34
Upside: +231.23%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Equal-Weight
Price Target: $405 → $475
Current: $463.43
Upside: +2.50%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $7.30
Upside: +242.47%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $7.44
Upside: +168.82%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.47
Upside: +790.69%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $10.70
Upside: +171.03%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.25
Upside: +788.89%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.38
Upside: +624.64%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $53.77
Upside: +78.54%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $17.12
Upside: +203.74%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $38.00
Upside: -28.95%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.65
Upside: +324.24%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $13.10
Upside: +106.11%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $2.08
Upside: +861.54%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.85
Upside: +1,068.83%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.79
Upside: +1,165.82%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.75
Upside: -36.84%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.98
Upside: +401.67%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $9.78
Upside: +5,012.47%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $33.53
Upside: +138.59%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $8.67
Upside: +73.01%